The latest update is out from Knight Therapeutics ( (TSE:GUD) ).
Knight Therapeutics Inc. has announced the acquisition of Paladin Pharma Inc. from Endo Operations Limited for $120 million, with potential future payments contingent on sales milestones. This strategic acquisition is expected to enhance Knight’s Canadian business and provide a stable cash flow to support growth in Canada and Latin America, pending regulatory approvals expected by mid-2025.
More about Knight Therapeutics
Knight Therapeutics Inc., based in Montreal, Canada, is a specialty pharmaceutical company that focuses on acquiring, in-licensing, and commercializing pharmaceutical products primarily for the Canadian and Latin American markets. The company operates in Latin America through its subsidiaries United Medical, Biotoscana Farma, and Laboratorio LKM, and its shares are traded on the TSX under the symbol GUD.
YTD Price Performance: 1.61%
Average Trading Volume: 1,478
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $376.7M
Find detailed analytics on GUD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com